Literature DB >> 33811295

An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.

Andreas Breenfeldt Andersen1, Glenn A Jacobson2, Jacob Bejder1, Dino Premilovac3, Stephen M Richards3, Jon J Rasmussen4, Søren Jessen1, Morten Hostrup5.   

Abstract

Some have questioned the evidence for performance-enhancing effects of several substances included on the World Anti-Doping Agency's Prohibited List due to the divergent or inconclusive findings in randomized controlled trials (RCTs). However, inductive statistical inference based on RCTs-only may result in biased conclusions because of the scarcity of studies, inter-study heterogeneity, too few outcome events, or insufficient power. An abductive inference approach, where the body of evidence is evaluated beyond considerations of statistical significance, may serve as a tool to assess the plausibility of performance-enhancing effects of substances by also considering observations and facts not solely obtained from RCTs. Herein, we explored the applicability of an abductive inference approach as a tool to assess the performance-enhancing effects of substances included on the Prohibited List. We applied an abductive inference approach to make inferences on debated issues pertaining to the ergogenic effects of recombinant human erythropoietin (rHuEPO), beta2-agonists and anabolic androgenic steroids (AAS), and extended the approach to more controversial drug classes where RCTs are limited. We report that an abductive inference approach is a useful tool to assess the ergogenic effect of substances included on the Prohibited List-particularly for substances where inductive inference is inconclusive. Specifically, a systematic abductive inference approach can aid researchers in assessing the effects of doping substances, either by leading to suggestions of causal relationships or identifying the need for additional research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33811295     DOI: 10.1007/s40279-021-01450-9

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  167 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

Review 2.  Selected issues in the design and analysis of sport performance research.

Authors:  G Atkinson; A M Nevill
Journal:  J Sports Sci       Date:  2001-10       Impact factor: 3.337

3.  Design and analysis of research on sport performance enhancement.

Authors:  W G Hopkins; J A Hawley; L M Burke
Journal:  Med Sci Sports Exerc       Date:  1999-03       Impact factor: 5.411

4.  The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?

Authors:  Jeremy Howick; Paul Glasziou; Jeffrey K Aronson
Journal:  J R Soc Med       Date:  2009-05       Impact factor: 5.344

Review 5.  Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature.

Authors:  R Hausmann; S Hammer; P Betz
Journal:  Int J Legal Med       Date:  1998       Impact factor: 2.686

6.  Strengths and limitations of meta-analysis: larger studies may be more reliable.

Authors:  M D Flather; M E Farkouh; J M Pogue; S Yusuf
Journal:  Control Clin Trials       Date:  1997-12

7.  Current Anti-Doping Crisis: The Limits of Medical Evidence Employing Inductive Statistical Inference.

Authors:  Perikles Simon; Ulrich Dettweiler
Journal:  Sports Med       Date:  2019-04       Impact factor: 11.136

Review 8.  Pooling research results: benefits and limitations of meta-analysis.

Authors:  J P Ioannidis; J Lau
Journal:  Jt Comm J Qual Improv       Date:  1999-09

Review 9.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

10.  The effect of publication bias magnitude and direction on the certainty in evidence.

Authors:  Mohammad Hassan Murad; Haitao Chu; Lifeng Lin; Zhen Wang
Journal:  BMJ Evid Based Med       Date:  2018-04-12
View more
  1 in total

1.  The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial.

Authors:  Martina Zügel; Daniel A Bizjak; Dorle Nussbaumer; Kay Winkert; Kensuke Takabayashi; Johannes Kirsten; Mickel Washington; Gunnar Treff; Jens Dreyhaupt; Luise Steeb; Patrick Diel; Maria Kristina Parr; Jürgen M Steinacker; Hasema Persch
Journal:  Trials       Date:  2021-12-11       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.